Janus Henderson Group PLC Raises Position in Xenon Pharmaceuticals Inc. $XENE

Janus Henderson Group PLC grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 2.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,175,982 shares of the biopharmaceutical company’s stock after acquiring an additional 91,948 shares during the period. Janus Henderson Group PLC’s holdings in Xenon Pharmaceuticals were worth $242,858,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in Xenon Pharmaceuticals by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 396,138 shares of the biopharmaceutical company’s stock valued at $23,035,000 after buying an additional 8,980 shares during the period. Peregrine Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at $7,837,000. Jennison Associates LLC increased its stake in shares of Xenon Pharmaceuticals by 13.8% in the 4th quarter. Jennison Associates LLC now owns 1,292,055 shares of the biopharmaceutical company’s stock valued at $57,910,000 after acquiring an additional 156,820 shares in the last quarter. Siren L.L.C. lifted its position in shares of Xenon Pharmaceuticals by 62.2% during the 1st quarter. Siren L.L.C. now owns 1,318,564 shares of the biopharmaceutical company’s stock valued at $76,674,000 after acquiring an additional 505,803 shares during the period. Finally, NEXTBio Capital Management LP acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at $8,234,000. 95.45% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Performance

XENE stock opened at $64.19 on Friday. The business has a 50-day simple moving average of $59.13 and a two-hundred day simple moving average of $53.34. The company has a market capitalization of $6.21 billion, a P/E ratio of -13.66 and a beta of 0.61. Xenon Pharmaceuticals Inc. has a 52-week low of $30.00 and a 52-week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same period in the previous year, the company earned ($0.83) earnings per share. As a group, sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on XENE. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price target on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Needham & Company LLC reduced their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Royal Bank Of Canada raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. upped their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $77.20.

Insiders Place Their Bets

In other news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.91% of the stock is owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.